Compare Cenovus Energy Inc (CVE) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Eli Lilly And Co — how do they compare? Cenovus Energy Inc trades at $31.4 (market cap $57.90B), while Eli Lilly And Co trades at $1,169.35 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 18× Cenovus Energy Inc's market cap, and Cenovus Energy Inc pays the higher dividend (1.97%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Eli Lilly And Co for 93 Days on average.
| CVE | LLY | |
|---|---|---|
Market Cap | $57.90B | $1.04T |
Volume | 7,863,588 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $33.92 | $1.28K |
52-Week Low | $15.85 | $799.57 |
Typical Hold Time | 46 Days | 93 Days |
Enterprise Value | $63.84B | $1.09T |
Dividend Yield | 1.97% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 20.96% ROE and 11.48% net margin, supported by recent earnings beats. Cash flow trends indicate operational strength, though net cash flow was negative $353 million in 2025. Analyst sentiment is mixed with 40.74% buy ratings, while recent news highlights growth potential and value attributes.
Outlook: CVE offers value with a low P/E of 12.43 and solid earnings growth projections, but faces headwinds from volatile oil prices and mixed technical indicators. Risks include energy market fluctuations and debt levels, though institutional interest remains steady. The stock presents a balanced opportunity for value investors seeking energy exposure.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
